Core Points - BriaCell Therapeutics Corp. completed a share consolidation on January 24, 2025, at a ratio of one post-Consolidation Common Share for every fifteen pre-Consolidation Common Shares to comply with Nasdaq listing requirements [1][3] - The post-Consolidation Common Shares will begin trading on the TSX and Nasdaq on January 29, 2025, under the symbols "BCT" and "BCTX" respectively, with a new CUSIP number: 107930208 [2] - The total number of Common Shares reduced from 44,204,061 to 2,946,940 as a result of the consolidation [3] - Fractional Common Shares less than one-half have been cancelled, while those at least one-half have been converted to one whole Common Share [4] - Shareholders holding physical share certificates must submit a Letter of Transmittal to receive post-consolidated shares, while those with book shares will have their pre-consolidated shares automatically rendered void [5] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [6]
BriaCell Announces Completion of 15:1 Share Consolidation